Abstract
Hydroquinone and tranexamic acids (TXA) are skin-lightening agents with a hydrophilic nature and low skin absorption. A high dose is needed for clinical use, resulting in a high incidence of skin irritation. Co-drugs formed by conjugating hydroquinone and TXA were synthesized and their in vitro and in vivo skin absorption characteristics were evaluated. The two synthesized co-drugs were 4-hydroxyphenyl 4-(aminomethyl)cyclohexanecarboxylate (HAC) and 1,4- phenylene bis(aminomethyl)cyclohexanecarboxylate (BAC). The co-drugs were chemically stable in aqueous solution, but rapidly degraded to the respective parent drug in esterases and skin homogenates. Compared to hydroquinone application, 7.2- and 2.4-fold increments in the hydroquinone skin deposition were obtained with the in vitro application of HAC and BAC. HAC and BAC led to 3- and 2-fold enhancements of equivalent TXA deposition compared to TXA administration. The in vivo experiment showed a further enhancement of co-drugs compared to the in vitro setup. The transdermal penetration of co-drugs, especially BAC, was much lower than that of hydroquinone and TXA. This indicated high-level skin targeting by the co-drugs. HAC and BAC revealed strong affinities for the viable epidermis/dermis. Hair follicles are important reservoirs for co-drug delivery. Daily administration of co-drugs to the skin did not generate irritation for up to 7 days. Both co-drugs are superior candidates for treating skin hyperpigmentation.
Keywords: Hydroquinone, tranexamic acid, co-drug, skin targeting, hyperpigmentation.
Current Medicinal Chemistry
Title:Co-Drug Strategy for Promoting Skin Targeting and Minimizing the Transdermal Diffusion of Hydroquinone and Tranexamic Acid
Volume: 20 Issue: 32
Author(s): Pei-Wen Hsieh, Wei-Yu Chen, Ibrahim. A. Aljuffali, Chun-Che Chen and Jia-You Fang
Affiliation:
Keywords: Hydroquinone, tranexamic acid, co-drug, skin targeting, hyperpigmentation.
Abstract: Hydroquinone and tranexamic acids (TXA) are skin-lightening agents with a hydrophilic nature and low skin absorption. A high dose is needed for clinical use, resulting in a high incidence of skin irritation. Co-drugs formed by conjugating hydroquinone and TXA were synthesized and their in vitro and in vivo skin absorption characteristics were evaluated. The two synthesized co-drugs were 4-hydroxyphenyl 4-(aminomethyl)cyclohexanecarboxylate (HAC) and 1,4- phenylene bis(aminomethyl)cyclohexanecarboxylate (BAC). The co-drugs were chemically stable in aqueous solution, but rapidly degraded to the respective parent drug in esterases and skin homogenates. Compared to hydroquinone application, 7.2- and 2.4-fold increments in the hydroquinone skin deposition were obtained with the in vitro application of HAC and BAC. HAC and BAC led to 3- and 2-fold enhancements of equivalent TXA deposition compared to TXA administration. The in vivo experiment showed a further enhancement of co-drugs compared to the in vitro setup. The transdermal penetration of co-drugs, especially BAC, was much lower than that of hydroquinone and TXA. This indicated high-level skin targeting by the co-drugs. HAC and BAC revealed strong affinities for the viable epidermis/dermis. Hair follicles are important reservoirs for co-drug delivery. Daily administration of co-drugs to the skin did not generate irritation for up to 7 days. Both co-drugs are superior candidates for treating skin hyperpigmentation.
Export Options
About this article
Cite this article as:
Hsieh Pei-Wen, Chen Wei-Yu, Aljuffali A. Ibrahim., Chen Chun-Che and Fang Jia-You, Co-Drug Strategy for Promoting Skin Targeting and Minimizing the Transdermal Diffusion of Hydroquinone and Tranexamic Acid, Current Medicinal Chemistry 2013; 20 (32) . https://dx.doi.org/10.2174/15672050113109990202
DOI https://dx.doi.org/10.2174/15672050113109990202 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synthesis and Anticancer Activity of Some 2-[3/4-(2-Substituted Phenyl-2- oxoethoxy)benzylidene]-6-substituted-2,3-dihydro-1H-inden-1-one Derivatives
Letters in Drug Design & Discovery AGE-RAGE System and Carcinogenesis
Current Pharmaceutical Design Is there U-turn from Insulin Back to Pills in Diabetes?
Current Vascular Pharmacology Polyunsaturated Fatty Acids and Cardiovascular Disease
Current Pharmaceutical Design Targeting the Cancer-Stroma Interaction: A Potential Approach for Pancreatic Cancer Treatment
Current Pharmaceutical Design The Chemical Structure and Bioactivity of Cycloartane-type Compounds
Current Organic Chemistry Discovery of STAT3 Inhibitors: Recent Advances and Future Perspectives
Current Medicinal Chemistry Interstitial Lung Disease in Systemic Sclerosis: Pathophysiology, Current and New Advances in Therapy
Inflammation & Allergy - Drug Targets (Discontinued) Expressional Analysis and Role of Calcium Regulated Kinases in Abiotic Stress Signaling
Current Genomics The Role of Antihistamines in the Management of Allergic Rhinitis
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents New Oral Anticoagulants in Prophylaxis of Venous Thromboembolic Disease in Major Orthopedic Surgery
Cardiovascular & Hematological Disorders-Drug Targets Recent Developments of Thalidomide Derivatives Possessing Anti-Inflammatory Activity
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Synergistic Use of Computation, Chemistry and Biology to Discover Novel Peptide-Based Drugs: The Time is Right
Current Pharmaceutical Design Morphological and Functional Characteristic of Senescent Cancer Cells
Current Drug Targets Evaluation of Antidiabetic Activity of Carnosol (Phenolic Diterpene in Rosemary) in Streptozotocin-Induced Diabetic Rats
Cardiovascular & Hematological Disorders-Drug Targets Mesenchymal Stem Cells and their Exosomes: Promising Therapeutics for Chronic Pain
Current Stem Cell Research & Therapy 99mTechnetium- or Cy7-Labeled Fab(Tocilizumab) as Potential Multiple Myeloma Imaging Agents
Anti-Cancer Agents in Medicinal Chemistry Interleukin-19 as an Immunoregulatory Cytokine
Current Molecular Pharmacology CFTR Modulators and Reduction of Airway Inflammation in Cystic Fibrosis: How Much is Enough?
Current Medicinal Chemistry Recent Advances and Future Directions in the Management of Metastatic Renal Cell Carcinoma
Anti-Cancer Agents in Medicinal Chemistry